Compare VRTS & IOVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | VRTS | IOVA |
|---|---|---|
| Founded | 1988 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Investment Managers | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 992.3M | 1.7B |
| IPO Year | 1995 | 2008 |
| Metric | VRTS | IOVA |
|---|---|---|
| Price | $131.31 | $3.77 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 5 | 10 |
| Target Price | ★ $171.60 | $9.11 |
| AVG Volume (30 Days) | 66.6K | ★ 17.3M |
| Earning Date | 04-24-2026 | 05-07-2026 |
| Dividend Yield | ★ 7.38% | N/A |
| EPS Growth | ★ 18.24 | 14.84 |
| EPS | ★ 19.97 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $49.14 |
| Revenue Next Year | $3.84 | $51.69 |
| P/E Ratio | $6.58 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $124.70 | $1.64 |
| 52 Week High | $214.88 | $5.63 |
| Indicator | VRTS | IOVA |
|---|---|---|
| Relative Strength Index (RSI) | 38.79 | 49.74 |
| Support Level | N/A | $1.99 |
| Resistance Level | $169.44 | $4.34 |
| Average True Range (ATR) | 4.72 | 0.44 |
| MACD | 0.04 | -0.11 |
| Stochastic Oscillator | 35.64 | 9.71 |
Virtus Investment Partners Inc provides investment management and related services to institutions and individuals. It uses a multi-manager, multi-style approach, offering investment strategies from investment managers, each having its distinct investment style, autonomous investment process, and individual brand, as well as from select unaffiliated managers for certain funds. Through its multi-manager model, the group provides investment managers with distribution, business, and operational support. The Company operates in one business segment, namely as an asset manager providing investment management and related services for individual and institutional clients.
Iovance Biotherapeutics Inc is a clinical-stage biopharmaceutical company, pioneering a transformational approach to treating cancer by harnessing the human immune system's ability to recognize and destroy diverse cancer cells using therapies personalized for each patient. The company is preparing for potential U.S. regulatory approvals and commercialization of the first autologous T-cell therapy to address a solid tumor cancer. It operates in one segment, focusing on innovating, developing, and commercializing therapies using its autologous TIL cell therapies for patients with solid tumor cancers. Geographically, the company operates in United States and Rest of the World.